Elevance Health stock gained 1.25 percent on October 2

Published on 10/04/2026 at 18:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elevance Health stock traded at USD 386.43 on October 2, 2026, while its 52-week high was USD 436.24. Q2 revenue reached USD 49.83 billion.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) stock was last at USD 386.43 on the NYSE on October 2, 2026 at 4:00 p.m. ET, up 1.25 percent from the prior session. MarketBeat reported on October 3 that the shares traded below their 50-day moving average, with a session low of USD 380.65 against the USD 397.84 average.

Second-quarter figures beat consensus

Elevance Health reported second-quarter 2026 operating revenue of USD 49.83 billion and adjusted EPS of USD 7.45. Yahoo Finance said the revenue figure was 0.8 percent higher than a year earlier, while adjusted EPS in the quarter was expected at USD 4.72 before the report.

The quarterly revenue also stood USD 0.95 billion above the USD 48.88 billion analyst estimate cited by MarketBeat. The comparison matters because the company is entering the third quarter with medical-cost pressure still central to its earnings profile.

Guidance keeps the earnings floor visible

In a September 10, 2026 filing, Elevance Health reaffirmed full-year 2026 earnings guidance of at least USD 20.10 per diluted share, including USD 6.90 per share of net unfavorable items. Adjusted earnings guidance remained at least USD 27.00 per diluted share.

The same filing kept benefit expense ratio guidance at 90.2 percent plus or minus 50 basis points. That ratio gives investors a direct operating checkpoint for the balance between premium revenue and medical costs as the year progresses.

Analysts see value above the market price

MarketScreener listed a Buy mean consensus from 22 analysts and an average price target of USD 451.38. The target lies 16.8 percent above the USD 386.43 reference price, while BofA Securities raised its target from USD 460 to USD 480 on September 11, 2026, according to the same published market report.

Elevance Health operates health benefits and related healthcare services across commercial, Medicare and Medicaid markets, with offerings that include managed care and pharmacy solutions, according to MarketBeat. This mix makes enrollment, utilization and reimbursement conditions important alongside the headline EPS guidance.

Stock remains below its yearly high

At USD 386.43 on October 2, 2026, Elevance Health stock was 11.4 percent below its 52-week high of USD 436.24 and above its 52-week low of USD 274.84. Its market capitalization was USD 83.8 billion, with volume of 889,961 shares on the same date.